
0:00
44:37
In this special WCLC 2026 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu recap key findings from day three of the conference, featuring major advances that move targeted therapies earlier in the treatment of lung cancer.
Guests Dr. Julia Rotow, Dr. Roy Herbst, and Dr. Daniel Tan discuss new data from DESTINY-Lung04, ADAURA, and REZILIENT3 and what these findings could mean for clinical practice.
Guests:
Dr. Julia Rotow
Clinical Director and Research Director, Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Dr. Roy Herbst
Director, Dartmouth Cancer Center
Professor, Geisel School of Medicine at Dartmouth
Dr. Daniel Shao-Weng Tan
Senior Consultant Medical Oncologist at Division of Medical Oncology, National Cancer Centre Singapore
Professor, Duke-NUS Medical School
Senior Clinician-Scientist, Genome Institute of Singapore
Weitere Episoden von „Lung Cancer Considered“



Verpasse keine Episode von “Lung Cancer Considered” und abonniere ihn in der kostenlosen GetPodcast App.








